Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OligoG inhalation dose-finding study in cystic fibrosis
2018-000378-30Phase 2Terminated
- Sponsor
- AlgiPharma
- Start
- Jun 2019
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OligoG in cystic fibrosis (CF) (4 arms), sponsored by AlgiPharma. Primary endpoint: Relative change in FEV1. Started Jun 2019; status: terminated.
02
Drugs
OligoG
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2018-000378-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000378-30.